Proteon Therapeutics (NASDAQ:PRTO) Earns Media Sentiment Score of 0.06
Media coverage about Proteon Therapeutics (NASDAQ:PRTO) has been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Proteon Therapeutics earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the company’s share price in the near future.
Proteon Therapeutics (NASDAQ PRTO) remained flat at $1.30 during midday trading on Thursday. 31,986 shares of the company’s stock were exchanged. The firm’s 50-day moving average price is $1.37 and its 200-day moving average price is $1.57. The company’s market cap is $22.90 million. Proteon Therapeutics has a 1-year low of $1.10 and a 1-year high of $11.45.
Proteon Therapeutics (NASDAQ:PRTO) last announced its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.39) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.04. On average, analysts predict that Proteon Therapeutics will post ($1.65) EPS for the current fiscal year.
Several research analysts have recently issued reports on the company. HC Wainwright set a $3.00 price objective on Proteon Therapeutics and gave the company a “hold” rating in a research note on Saturday, May 13th. Maxim Group set a $6.00 target price on Proteon Therapeutics and gave the company a “buy” rating in a report on Thursday, May 4th. Finally, Zacks Investment Research cut Proteon Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company. Proteon Therapeutics has a consensus rating of “Hold” and a consensus target price of $8.14.
About Proteon Therapeutics
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Stock Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related stocks with our FREE daily email newsletter.